87 results
8-K
EX-99.1
BFRI
Biofrontera Inc
3 May 24
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
9:15am
the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes
8-K
EX-99.1
BFRI
Biofrontera Inc
26 Mar 24
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
4:45pm
disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare
8-K
EX-99.1
BFRI
Biofrontera Inc
15 Mar 24
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
5:20pm
ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage
8-K
EX-10.1
rdrbtvp1hfhsk2nldi
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
8-K
EX-99.1
mlbja0miyb5gzfujp
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
8-K
et67lj
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
sgdwqha ck1
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.2
qbkhg0ox2f
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
8-K
EX-99.1
7jvkk4hcl1k
5 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz® to Permit Up to Three Tubes per Use
5:25pm
8-K
EX-99.1
hd3a0cw jk29gex6yazv
11 Jan 24
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
4:40pm
8-K
EX-99.1
yibp mnx4m7
9 Nov 23
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
5:15pm
8-K
EX-99.1
n9ul odxpjmto1merx
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
424B4
0m3aeuph 2oz
1 Nov 23
Prospectus supplement with pricing info
5:09pm